Efficacy Outcomes of Repotrectinib in Patients with NTRK-positive Solid Tumours By Ogkologos - February 10, 2026 218 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TRIDENT-1 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Artificial Intelligence for Diagnosis and Gleason Grading of Prostate Cancer January 24, 2022 Ahead of a Key Meeting of EU Health Ministers, ESMO Calls... June 14, 2026 2023 ASCO Annual Meeting Research Round Up: Progress in Preventing Melanoma... September 12, 2023 VA Study Finds No Disparities in Prostate Cancer Deaths with Equal... February 18, 2020 Load more HOT NEWS Noninferiority of OS with 3 Months Compared to 6 Months of... Phase II LCMC3 Study of Neoadjuvant Atezolizumab Met Primary Endpoint with... Results of Continuous vs Intermittent Dosing Schedules of BRAF/MEK Inhibitor Combination... FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection
